China Biotech Services Holdings Limited (8037.HK)
HKD 0.37
(-8.75%)
HKD 0.37
(-8.75%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 192.57 Million | 482.74 Million | 40.5 Million | 421.99 Million | -30.3 Million | -14.75 Million |
| Net Income | -95.44 Million | 862.82 Million | 180.66 Million | 202.8 Million | -109.59 Million | -69.24 Million |
| Depreciation & Amortization | 55.58 Million | 66.4 Million | 68.11 Million | 40.33 Million | 20.2 Million | 8.48 Million |
| Deferred income taxes | 381.72 Million | - | 7.82 Million | -3.87 Million | 33.42 Million | -2.76 Million |
| Stock-based compensation | 1.88 Million | 2.01 Million | 5.24 Million | 9.11 Million | 10.53 Million | 12.25 Million |
| Change in working capital | 494.77 Million | -433.3 Million | -225.52 Million | 172.64 Million | 22.65 Million | 33.05 Million |
| Other non-cash items | -645.94 Million | -15.18 Million | 4.18 Million | 983 Thousand | -7.53 Million | 3.45 Million |
| Investing Cash Flow | -55.41 Million | -256.31 Million | -8.12 Million | -126.24 Million | -100.23 Million | -36.53 Million |
| Investments in PPE | -62.88 Million | -69.75 Million | -12.21 Million | -126.6 Million | -7.35 Million | -6.49 Million |
| Acquisitions | 7.47 Million | -6.49 Million | 490 Thousand | 129 Thousand | -54.66 Million | 2.07 Million |
| Investment purchases | - | -51.76 Million | -490 Thousand | - | -39.2 Million | -39.28 Million |
| Sales/Maturities of investments | - | 69 Thousand | 4.08 Million | - | - | 2.19 Million |
| Other Investing Activities | -6.25 Million | -128.37 Million | 12 Thousand | 223 Thousand | 989 Thousand | 4.97 Million |
| Financing Cash Flow | -149.41 Million | -281.95 Million | -266.61 Million | 43.93 Million | 23.07 Million | 132.63 Million |
| Debt repayment | -31.05 Million | -8.15 Million | -52.24 Million | -23.93 Million | -5.66 Million | -5.31 Million |
| Dividends payments | -9.63 Million | - | - | - | - | - |
| Common Stock Repurchased | -3.63 Million | -2.98 Million | -4.31 Million | -4.5 Million | -509 Thousand | -874 Thousand |
| Common Stock Issuance | - | - | - | 109 Thousand | 11.6 Million | 132.09 Million |
| Other Financing Activities | -156 Million | -270.82 Million | -210.06 Million | 72.38 Million | 33.35 Million | 6.72 Million |
| Accounts receivables | 729.88 Million | -656.42 Million | -64.85 Million | -22.22 Million | 20.62 Million | 26.83 Million |
| Accounts payables | -232.89 Million | 237.1 Million | -158.27 Million | 197.38 Million | 2.15 Million | 6.74 Million |
| Inventory | -2.22 Million | -13.98 Million | -2.4 Million | -2.51 Million | -115 Thousand | -528 Thousand |
| Other working capital | 1.44 Million | 7.8 Million | 68 Thousand | -100 Thousand | 4.76 Million | 33.58 Million |
| Cash at beginning of period | 92.77 Million | 150.55 Million | 384.53 Million | 45.51 Million | 154.47 Million | 73.18 Million |
| Cash at end of period | 206.89 Million | 92.77 Million | 150.55 Million | 384.53 Million | 45.51 Million | 154.47 Million |
| Capital Expenditure | -62.88 Million | -69.75 Million | -12.21 Million | -126.6 Million | -7.35 Million | -6.49 Million |
| Effect of forex changes on cash | -2.17 Million | -2.26 Million | 245 Thousand | -667 Thousand | -1.49 Million | -44 Thousand |
| Net cash flow / Change in cash | 114.12 Million | -57.78 Million | -233.98 Million | 339.02 Million | -108.96 Million | 81.29 Million |
| Free Cash Flow | 129.68 Million | 412.99 Million | 28.28 Million | 295.39 Million | -37.65 Million | -21.25 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -39.95 Million | -39.95 Million | -29.47 Million | -95.44 Million | -35.49 Million | -15.1 Million |
| Depreciation & Amortization | 6.45 Million | 6.45 Million | 20.23 Million | 55.58 Million | - | 35.34 Million |
| Deferred income taxes | - | - | - | 381.72 Million | - | - |
| Stock-based compensation | 152 Thousand | 152 Thousand | 1.88 Million | 1.88 Million | - | 533 Thousand |
| Change in working capital | - | - | - | 494.77 Million | - | - |
| Other non-cash items | -14.41 Million | -14.41 Million | 27.58 Million | -645.94 Million | 35.49 Million | 14.57 Million |
| Investing Cash Flow | -30.73 Million | -30.73 Million | 89.32 Million | -55.41 Million | - | -144.73 Million |
| Investments in PPE | -80.9 Million | -80.9 Million | - | -62.88 Million | - | - |
| Acquisitions | - | - | - | 7.47 Million | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 50.17 Million | 50.17 Million | - | -6.25 Million | - | - |
| Financing Cash Flow | 59.27 Million | 59.27 Million | -138.57 Million | -149.41 Million | - | -10.83 Million |
| Debt repayment | - | - | - | -31.05 Million | - | - |
| Dividends payments | - | - | - | -9.63 Million | - | - |
| Common Stock Repurchased | - | - | - | -3.63 Million | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 59.27 Million | 59.27 Million | - | -156 Million | - | - |
| Accounts receivables | - | - | - | 729.88 Million | - | - |
| Accounts payables | - | - | - | -232.89 Million | - | - |
| Inventory | - | - | - | -2.22 Million | - | - |
| Other working capital | - | - | - | 1.44 Million | - | - |
| Cash at beginning of period | - | - | 245.39 Million | 92.77 Million | - | 92.77 Million |
| Cash at end of period | -19.42 Million | -19.42 Million | 206.89 Million | 206.89 Million | - | 245.39 Million |
| Capital Expenditure | -80.9 Million | -80.9 Million | - | -62.88 Million | - | - |
| Effect of forex changes on cash | -198.5 Thousand | -198.5 Thousand | 129.03 Million | -2.17 Million | - | -2.65 Million |
| Net cash flow / Change in cash | -19.42 Million | -19.42 Million | -38.5 Million | 114.12 Million | - | 152.62 Million |
| Free Cash Flow | -128.67 Million | -128.67 Million | -118.28 Million | 129.68 Million | - | 310.85 Million |
060280
VEOEY
JASH
603990
ECLERX
ELIN